Melanotan II: Complete Research Guide

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). It was originally developed at the University of Arizona in the 1990s by researchers Victor Hruby and Mac Hadley, who were investigating compounds that could stimulate melanogenesis — the natural tanning process — as a potential strategy for preventing skin cancer by increasing the skin's natural UV protection.

The peptide acts as a non-selective agonist at multiple melanocortin receptors (MC1R through MC5R), which gives it a broad range of biological effects beyond pigmentation alone. During clinical trials, researchers observed unexpected secondary effects, including appetite suppression and spontaneous penile erections in male subjects. These observations led to further research into its broader pharmacological profile.

Despite generating significant scientific interest, Melanotan II has never been approved for medical use by any regulatory authority worldwide. It remains one of the most widely discussed research peptides due to the visibility of its primary effect — skin darkening — and the strong consumer demand for sunless tanning. However, its non-selective receptor activity and lack of clinical safety data raise important concerns that researchers and the public should understand.

Melanotan II is a synthetic cyclic peptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ and a molecular weight of approximately 1,024 Da. It was designed as a more potent, more stable analogue of the endogenous hormone α-MSH, which is the body's natural trigger for melanin production.

The key structural modifications that distinguish Melanotan II from natural α-MSH include cyclisation of the peptide backbone (improving stability and receptor binding), substitution of methionine with norleucine (preventing oxidation), and incorporation of D-phenylalanine (enhancing potency and resistance to enzymatic degradation). These changes give MT-II a significantly longer biological half-life and greater potency compared to α-MSH.

Melanotan II is closely related to, but distinct from, Melanotan I (afamelanotide), which is a linear peptide with more selective MC1R activity. While Melanotan I received regulatory approval in Europe for treating a specific rare genetic condition (erythropoietic protoporphyria), Melanotan II remains unapproved due to its non-selective receptor activity.

In research and grey-market contexts, Melanotan II is typically supplied as a lyophilized powder for reconstitution and subcutaneous injection. It is also found in nasal spray formulations, though these are generally considered less bioavailable and less studied.

Melanotan II exerts its effects through activation of melanocortin receptors, a family of five G-protein-coupled receptors (MC1R through MC5R) that mediate a wide range of physiological functions.

MC1R — Pigmentation: Activation of MC1R on melanocytes (pigment-producing cells in the skin) is the primary mechanism behind MT-II's tanning effect. When MC1R is stimulated, it triggers the cAMP signalling cascade, activating the transcription factor MITF, which upregulates enzymes involved in eumelanin synthesis (tyrosinase, TRP-1, TRP-2). Eumelanin is the dark, photoprotective pigment responsible for tanning. This process occurs independently of UV exposure, producing a tan without sun damage.

MC3R and MC4R — Appetite and Sexual Function: MT-II's effects on appetite suppression are mediated through MC3R and MC4R activation in the hypothalamus. These same receptors, particularly MC4R, are responsible for the pro-erectile and pro-sexual effects observed in both male and female subjects. MC4R activation in the central nervous system modulates sexual arousal pathways through downstream effects on oxytocin and other neuropeptides.

MC5R — Exocrine Function: MC5R activation may influence sebaceous gland activity, though this effect is less well-characterised.

The non-selective nature of MT-II — activating multiple receptor subtypes simultaneously — is both the source of its broad pharmacological effects and the primary reason it has not been developed as a pharmaceutical drug. Selective compounds like PT-141 (MC3R/MC4R) and afamelanotide (MC1R) were developed from MT-II to isolate specific desired effects.

The broad melanocortin receptor activity of Melanotan II has generated research interest across several areas.

• Skin Pigmentation and Photoprotection: The original research purpose of MT-II was to increase eumelanin production as a strategy for skin cancer prevention. Studies have confirmed that it significantly increases skin pigmentation without UV exposure. A 2018 study published in the FASEB Journal demonstrated that subcutaneous MT-II administration induced robust melanogenesis with meaningful increases in melanin density.

• Sexual Dysfunction: Clinical trials in both men and women demonstrated pro-sexual effects. In men, MT-II induced erections in subjects with erectile dysfunction, including those who did not respond to sildenafil. In women, it increased subjective sexual desire and genital arousal. These findings led directly to the development of PT-141 (bremelanotide).

• Appetite and Body Composition: MC3R/MC4R activation suppresses appetite through hypothalamic pathways. Researchers have observed reduced food intake in subjects receiving MT-II. This has generated interest in the melanocortin system as a target for obesity research.

• Compulsive Behaviour Research: Emerging research has explored whether melanocortin system modulation could influence compulsive behaviours, including alcohol consumption and drug-seeking behaviour.

• Inflammatory Conditions: Some preclinical data suggest melanocortin agonists, including MT-II, may have anti-inflammatory properties relevant to conditions like inflammatory bowel disease.

As an unapproved research compound, there are no official dosage guidelines for Melanotan II. The following protocols are derived from published research literature and are for reference purposes only.

• Loading Phase: Research protocols typically begin with a loading phase of daily subcutaneous injections. Starting doses are commonly 0.25 mg, gradually increased to 0.5–1.0 mg per day over 1–2 weeks. This loading phase typically lasts 2–4 weeks, depending on the desired degree of pigmentation.

• Maintenance Phase: Once the desired level of pigmentation is achieved, the frequency is reduced to 1–2 injections per week at similar doses to maintain the effect.

• Administration: Subcutaneous injection, typically in the abdominal area. MT-II is supplied as a lyophilized powder and reconstituted with bacteriostatic water. Nasal spray formulations also exist but have lower and less predictable bioavailability.

• UV Exposure: Research indicates that while MT-II can increase pigmentation without UV exposure, combining it with moderate UV exposure significantly enhances and accelerates the tanning response.

It is important to note that dose-response relationships are highly individual, and the lack of standardised pharmaceutical-grade preparations means concentration and purity can vary between suppliers.

The safety profile of Melanotan II is a significant area of concern due to the lack of comprehensive clinical safety data and the compound's non-selective receptor activity.

Commonly Reported Side Effects: • Nausea (very common, especially in early use) • Facial flushing • Fatigue and drowsiness • Spontaneous or prolonged erections (in males) • Darkening of existing moles and nevi • Injection site reactions

Serious Safety Concerns: • Mole Changes: MT-II stimulates melanocytes non-selectively, including those in existing moles. There have been case reports of atypical mole changes and concern that it could potentially mask or promote melanoma, the very cancer it was designed to prevent. Several dermatology case reports have documented atypical naevi developing in individuals using MT-II. • Cardiovascular Effects: Some users have reported changes in blood pressure and heart rate. The cardiovascular safety profile has not been adequately characterised. • Rhabdomyolysis: Rare case reports have linked MT-II use to rhabdomyolysis (muscle tissue breakdown). • Priapism: Prolonged erections requiring medical intervention have been reported.

Health authorities in multiple countries, including the TGA in Australia and the FDA in the United States, have issued formal warnings against the use of Melanotan II, citing unknown long-term safety risks and the potential for serious adverse effects.

Melanotan II is not approved for any medical use in Canada. Health Canada has not authorised it as a drug, a natural health product, or a cosmetic ingredient for injection.

Health Canada has issued advisories warning consumers about the health risks associated with Melanotan II products. These advisories note that the safety and efficacy of these products have not been evaluated, and that their use could pose serious health risks.

The sale of Melanotan II for human use in Canada is illegal. It cannot be marketed as a drug, supplement, or health product. However, it can be obtained through research chemical suppliers under the premise of in-vitro or academic research use.

Importation of Melanotan II for personal use falls into a regulatory grey area. While Health Canada's personal importation policy allows limited importation of certain medications not available in Canada, this policy is intended for legitimate prescription medications from other jurisdictions, not for unapproved research chemicals.

Canadians should be aware that purchasing MT-II from unregulated online sources carries significant risks regarding product purity, sterility, and accurate dosing. Products seized and tested by regulatory agencies in various countries have been found to contain incorrect doses, contaminants, or entirely different substances.